BioSpace News Archive

Ronovo Surgical, an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery to address the tremendous needs of the Chinese surgical market, recently announced successful closing of Series A financing.

The AAD VMX 2021, a virtual meeting experience taking place April 23-25, will feature the latest information on skin, hair and nails, presented by world-renowned experts in the field of dermatology.

Taltz also helped patients stay on treatment longer and have more days without additional therapy in three real-world analyses of U.S. claims data

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, will present data from its two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 (tapinarof 1%, n=340; vehicle, n=170) and PSOARING 2 (tapinarof 1%, n=343; vehicle, n=172), at the American Academy of Dermatology Virtual Meeting Experience

Ronovo Surgical, an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery to address the tremendous needs of the Chinese surgical market, recently announced successful closing of Series A financing.

Bristol Myers Squibb (NYSE:BMY) today announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis.

The National Kidney Foundation (NKF) is pleased to announce the appointment of California businessman Alan C. Mendelson to its national Board of Directors.

Johnson & Johnson Consumer Health today presented findings from one of the first clinical studies examining a daily skincare regimen as adjunctive therapy for cancer patients at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021.

- Etrasimod 2 mg treatment group achieved statistical significance in the percentage change in weekly peak pruritis (PP-NRS), in the change in Dermatology Life Quality Index (DLQI), and in the change in Patient-Oriented Eczema Measure (POEM) - Etrasimod 2 mg was generally well tolerated, consistent with data in previous trials

UCB, a global biopharmaceutical company, today announced that 12 abstracts on bimekizumab, an investigational IL-17A and IL-17F inhibitor, in the treatment of adults with moderate to severe plaque psoriasis, will be presented at the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), April 23 - 25, 2021 .